Merck KGaA has moved court requesting that data pertaining to Enzene Biosciences’ biosimilar cetuximab, which has received regulatory approval in India, be placed in the public domain.
The German group has, in a case before the Delhi High Court versus the Drugs Controller General of India (DCGI)...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?